Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
醫療保健行業中超賣最多的股票爲買入被低估的公司提供了機會。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
RSI 是一種動量指標，它比較股票在價格上漲的日子和價格下跌的日子的走勢。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的數據，當相對強弱指數低於30時，資產通常被視爲超賣。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是該行業主要超賣參與者的最新名單，其相對強弱指數接近或低於30。
Corcept Therapeutics Incorporated (NASDAQ:CORT)
Corcept 治療公司（納斯達克股票代碼：CORT）
- On Nov. 1, 2023, Corcept Therapeutics announced the appointment of Monica Tellado as President, Emerging Markets. The company's stock has a 52-week low of $17.86 .
- RSI Value: 28.71
- CORT Price Action: Shares of Corcept Therapeutics fell 1.2% to close at $32.48 on Friday.
- 2023年11月1日，Corcept Therapeutics宣佈任命莫妮卡·泰拉多爲新興市場總裁。該公司的股票有 52 周低點爲 17.86 美元 。
- RSI 值：28.71
- CORT價格走勢：週五，Corcept Therapeutics的股價下跌1.2％，收於32.48美元。
Kintara Therapeutics, Inc. (NASDAQ:KTRA)
Kintara Therapeutics, Inc.（納斯達克股票代碼：KTRA）
- On Dec. 7, Kintara Therapeutics announced a review of strategic alternatives focused on maximizing stockholder value. The company's stock fell around 49% over the past month. It has a 52-week low of $0.16.
- RSI Value: 23.28
- KTRA Price Action: Shares of Kintara Therapeutics fell 12.1% to close at $0.1696 on Friday.
- 12月7日，Kintara Therapeutics宣佈對戰略替代方案進行審查，重點是實現股東價值最大化。該公司的股票在過去一個月中下跌了約49％。它 創下 52 周低點 0.16 美元。
- RSI 值：23.28
- KTRA價格走勢：週五，Kintara Therapeutics的股價下跌12.1％，收於0.1696美元。
Rapid Micro Biosystems, Inc. (NASDAQ:RPID)
快速微生物系統公司（納斯達克股票代碼：RPID）
- On Nov. 3, Rapid Micro Biosystems posted in-line loss for the third quarter. "We are pleased to report that we exceeded our revenue guidance for the third consecutive quarter this year," said Robert Spignesi, President and CEO. The company's stock fell around 20% over the past five days and has a 52-week low of $0.74.
- RSI Value: 25.60
- RPID Price Action: Shares of Rapid Micro Biosystems fell 15.4% to close at $0.74 on Friday.
- 11月3日，Rapid Micro Biosystems公佈了第三季度的同比虧損。總裁兼首席執行官羅伯特·斯皮格內西表示：“我們很高興地向大家報告，今年我們連續第三個季度收入超過預期。”該公司的股票在過去五天中下跌了約20％，爲期52周 最低價爲0.74美元。
- RSI 值：25.60
- RPID價格走勢：快速微生物系統的股價週五下跌15.4％，收於0.74美元。
Motus GI Holdings, Inc. (NASDAQ:MOTS)
Motus GI 控股有限公司（納斯達克股票代碼：MOTS）
- On Dec. 19, Motus GI Holdings announced the pricing of a $5 million public offering of 3,333,334 shares of common stock at $1.50 per share. The company's shares lost around 74% over the past month. The company's 52-week low is $1.14.
- RSI Value: 27.00
- MOTS Price Action: Shares of Motus GI Holdings fell 12.1% to close at $1.2750 on Friday.
- 12月19日，Motus GI Holdings宣佈以每股1.50美元的價格公開發行3,333,334股普通股，定價爲500萬美元。該公司的股價在過去一個月中下跌了約74％。該公司的52周低點爲1.14美元。
- RSI 值：27.00
- MOTS價格走勢：週五，Motus GI Holdings的股價下跌12.1％，收於1.2750美元。
Milestone Pharmaceuticals Inc. (NASDAQ:MIST)
里程碑製藥公司（納斯達克股票代碼：MIST）
- On Dec. 26, Milestone Pharmaceuticals announced that it received a Refusal to File letter from the FDA for the New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia. The company's shares fell around 42% over the past five days. The company has a 52-week low of $1.62.
- RSI Value: 27.64
- MIST Price Action: Shares of Milestone Pharmaceuticals fell 5.7% to close at $1.67 on Friday.
- 12月26日，Milestone Pharmicals宣佈，它收到美國食品藥品管理局拒絕提交用於治療陣發性室上性心動過速的自服依曲美爾鼻腔噴霧劑的新藥申請信。該公司的股價在過去五天中下跌了約42％。該公司 創下 52 周低點 爲1.62美元。
- RSI 值：27.64
- MIST價格走勢：週五，里程碑製藥的股價下跌5.7％，收於1.67美元。
Read More: Insiders Buying FedEx And 3 Other Stocks
閱讀更多： 內部人士買入聯邦快遞和其他3只股票
譯文內容由第三人軟體翻譯。